Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

Dudek, Magdalena; Harris, Leanne F.; Killard, Anthony J.

doi:10.1111/j.1751-553x.2010.01283.x

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a limited understanding of the contact pathway can be obtained through commonly used in vitro coagulation tests, for example measurements of the activated partial thomboplastin time (APTT) and prothrombin time (PT), which only record clotting time . By contrast, thromboelastography (TEG), a technique first developed in Germany in 1948, has evolved as a more comprehensive method to monitor coagulation from the beginning of clot formation to the end of fibrinolysis (see Figure ; more will be said below to explain this figure).…”

Section: Introductionmentioning

confidence: 99%

Thromboelastography (TEG) Cups and Pins with Different PECVD Coatings: Effect on the Coagulation Cascade in Platelet‐poor Blood Plasma

Contreras-García

Merhi

Ruíz

et al. 2013

Plasma Processes & Polymers

View full text Add to dashboard Cite

Thromboelastography uses cups and pins made of CyroliteW plastic to analyze the rate of fibrin clot formation in blood samples. In this study, TEG cups and pins were modified by 4 distinct coating types using plasma-enhanced chemical vapor deposition (PECVD): carboxylated, amine-rich, hydrophobic, SiO 2 , and analyzed for surface chemistry and wettability. We tested the hypothesis that the coagulation kinetics of recalcified citrated blood plasma is controlled by surface chemistry, in the absence of clot activator. Only carboxylated surfaces became negatively charged upon wetting, and accelerated clot formation in a highly reproducible manner, whereas Cyrolite W and the other coatings had delayed and unpredictable clotting times. These data are consistent with a model whereby carboxylated surfaces selectively adsorb and activate factor XII while repelling other more abundant anionic blood proteins, resulting in reproducible clot kinetics.

show abstract

Section: Introductionmentioning

confidence: 99%

Thromboelastography (TEG) Cups and Pins with Different PECVD Coatings: Effect on the Coagulation Cascade in Platelet‐poor Blood Plasma

Contreras-García

Merhi

Ruíz

et al. 2013

Plasma Processes & Polymers

View full text Add to dashboard Cite

show abstract

“…Samples visually seem haemolysed via haemoglobin substitution, should not be rejected and must be analysed with mechanical or electromechanical clot detection method [20]. The best way to choose correct method when existing studies which were done with analytical systems and reagents combination and studied how haemolysis impact on routine (PT, APTT, fibrinogen) tests [21].…”

Section: Haemolysis Impact For Coagulationmentioning

confidence: 99%

Plasma for Laboratory Diagnostics

Sepetiene¹,

Sidlauskiene²,

Patamsytė³

2018

Plasma Medicine - Concepts and Clinical Applications

View full text Add to dashboard Cite

Main clinical and scientific aspects of methodology how to choose the right sample for testing to be involved in Plasma for Laboratory Diagnostics chapter as plasma is in use sufficiently widely. Different approach by clinical and research laboratories formed the necessity to discuss the basic laboratory terms and conditions to obtain correct results. Evaluation of preanalytical variables with impact on handling, processing and storage of samples with subsequent meaning for laboratory test results should be known by physicians, biomedical scientists, laboratory technicians and so on. The impact of chemical additives for diagnostics tools, the differences between plasma and serum samples for different laboratory tests and the subsequent analysis, management and traceability of specimens with standardisation value should be taken into account.

show abstract

Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants

Baruch

2013

Postgraduate Medicine

View full text Add to dashboard Cite

Novel oral anticoagulants, direct thrombin inhibitors, and factor Xa inhibitors are being introduced into clinical practice. In contrast to vitamin K antagonists, such as warfarin, these novel agents, because of their relatively wide therapeutic range and predictable pharmacokinetics, have been evaluated in clinical trials and approved for clinical use without the need for routine coagulation monitoring. On occasion, it will be important to assess the anticoagulant status of patients treated with these agents. As a result of their targeted mechanisms of action, they affect standard coagulation assays differently than vitamin K antagonists and heparins, and such assay results may not provide clinically useful information. Thus, less commonly used coagulation assays (eg, chromogenic anti-factor Xa activity assays, diluted thrombin time, and ecarin-based clotting tests) may be introduced into clinical practice. These assays are currently limited by the absence of validated therapeutic targets and lack of standardization across laboratories, vendors, and medication classes. This article provides an overview of the coagulation assays and their potential role in determining the anticoagulant status of patients treated with the emerging anticoagulants.

show abstract

Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

Cited by 3 publications

References 27 publications

Thromboelastography (TEG) Cups and Pins with Different PECVD Coatings: Effect on the Coagulation Cascade in Platelet‐poor Blood Plasma

Thromboelastography (TEG) Cups and Pins with Different PECVD Coatings: Effect on the Coagulation Cascade in Platelet‐poor Blood Plasma

Plasma for Laboratory Diagnostics

Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants

Contact Info

Product

Resources

About